C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on April 14, 2025, regarding an event that occurred on April 10, 2025. The Company is a Delaware corporation with its principal executive offices in Watertown, MA, and its common stock trades on the Nasdaq Global Select Market under the symbol CCCC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director:
- Event: Bruce Downey notified the Board of his intention to retire and not stand for reelection at the 2025 Annual Meeting of Stockholders.
- Effective Date: Mr. Downey will cease to serve as a director following the 2025 Annual Meeting.
- Reason: The departure is not due to any disagreements with the Company regarding strategy, operations, policies, or practices.
- Committee Roles Affected: Mr. Downey will no longer serve as Chair and member of the Organization, Leadership and Compensation Committee, member of the Audit Committee, or member of the Nominating and Corporate Governance Committee.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors beyond the standard disclosure of the director's departure.
Key Facts for Investor Verification
- Confirm the date of the 2025 Annual Meeting of Stockholders to determine the exact date Mr. Downey's resignation becomes effective.
- Verify if the Company has announced a nominee to replace Mr. Downey on the Board or his specific committee roles.
- Review the Company's proxy statement for the 2025 Annual Meeting for further details on the Board composition and election process.